Broad研究所发现靶向TMED7可改善小鼠多型蛋白病
Targeting a cellular 'traffic jam' treats multiple diseases in mice
Broad研究所研究人员在Neuron发表研究发现,靶向TMED7蛋白可在MUC1肾病和视网膜色素变性两种小鼠模型中释放错误折叠蛋白堆积。研究揭示TMED2/7/9/10形成复合物捕获错误折叠蛋白,敲除TMED7后可恢复细胞正常功能而不影响其他TMED蛋白作用。研究者认为该机制可能适用于多种蛋白病治疗。
A single therapy may be able to treat inherited disorders of both the kidneys and eyes—and potentially more genetic diseases called proteinopathies, researchers at the Broad Institute have discovered.
The diseases are all caused by mutated proteins that don't fold correctly and end up accumulating, eventually killing cells. The new therapeutic approach unclogs the traffic jam of misfolded proteins by targeting an entrapment complex, a malfunctioning arm of the cell's trafficking machinery.
In 2019, the same team of researchers reported the role of one protein in the cell, TMED9, in causing accumulation of misfolded proteins in a rare disease called MUC1 kidney disease. Now, they've shown that TMED9 is part of a larger complex that includes four proteins—TMED2, 7, 9 and 10—and that a small molecule they developed to target this machine works in mice against both MUC1 kidney disease and the rare genetic eye disorder retinitis pigmentosa.
The new work is published in the journal Neuron.
"We've identified a shared mechanism behind many seemingly disparate diseases that, on their own, are each quite rare and don't drive a lot of investment for therapeutic development," said Anna Greka, a core institute member of the Broad and senior author of the new paper. "But put all these conditions together, and a drug treating all of them is suddenly something that could benefit millions of patients."
Greka adds that the new study is evidence of "nodal biology"—where different diseases share common biological "nodes" or mechanisms that can be targeted by the same drug. Indeed, she and her collaborators are now testing different TMED-targeting molecules in liver and brain diseases. This effort is part of the Ladders to Cures Accelerator at Broad, which Greka founded with the goal to speed up the development of these kinds of treatments and cures.
"This paper is laying the foundation for some of these future therapeutic programs," said Greka, who is also a professor at Harvard Medical School and a physician in the Department of Medicine at Mass General Brigham.
When quality control goes wrong
More than 50 inherited diseases, known as proteinopathies, are caused when a misfolded protein accumulates in cells. These diseases can affect different organs such as the liver, eye or brain.
In 2019, Greka's group showed that for one proteinopathy, MUC1 kidney disease, misfolded proteins were accumulating because TMED9, meant to shuttle the proteins through the cell's quality-control system, was overwhelmed. Since the cell couldn't repair the mutated protein's structure, TMED9 remained latched onto it, causing the entire protein production and quality-control system to become jammed. Disabling TMED9, they discovered at the time, released the misfolded protein to be recycled by the cell's lysosome, letting traffic flow normally again. Initial data suggested that the same thing was happening in other proteinopathies.
"Our first thought was that by uncovering the role of TMED9, we'd solved the problem," said Greka. "But then we realized these TMED proteins come in nine different versions, and those nine versions can be combined in all sorts of ways."
In the new work, the team analyzed how each of the nine TMED proteins could work together and which of them played a role in the quality-control system that went awry in MUC1 kidney disease. They discovered that TMED2, 7, 9 and 10 come together to form a complex that traps misfolded proteins.
"All those TMEDs have regular roles in quality control in healthy cells," said Magdalena Riedl Khursigara, a postdoctoral fellow in Greka's lab and co-first author of the new work along with Alissa Goss, who was previously an M.D.-Ph.D. student in the Greka lab at Broad and is now a resident in internal medicine at Washington University in St. Louis.
"Misfolding happens all the time on a low level and this complex handles it. But in these genetic disorders, there's just a huge amount of misfolded protein burden, because it's continuously being produced due to a genetic mutation."
One node, many diseases
One protein in particular—TMED7—played a particularly potent role in holding the complex in place. Greka, Riedl Khursigara and colleagues showed that deleting the gene for TMED7 reversed the hallmarks of disease in mice with MUC1 kidney disease and slowed vision loss in a mouse model of retinitis pigmentosa.
Importantly, removing TMED7 stopped the buildup of mutated proteins but didn't prevent the TMEDs from carrying out their normal function.
"If you knock out just TMED7 in a genetic model, then the entrapment of misfolded proteins is released but the other TMEDs remain stable," said Riedl Khursigara. "That's why we think this is an especially good protein to target."
The scientists say that the kidney and eye proteinopathies they studied could represent the tip of the iceberg of what a TMED-targeting therapeutic strategy could treat. Based on their latest findings, they are now developing drug candidates that specifically target TMED7. These drugs, the team hypothesizes, could treat a wide range of proteinopathies.
Publication details
Disrupting a cargo receptor entrapment complex is a therapeutic node for distinct proteinopathies, Neuron (2026). DOI: 10.1016/j.neuron.2026.10.023. www.cell.com/neuron/fulltext/S0896-6273(26)00819-6
Journal information: Neuron
Key medical concepts
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Targeting a cellular 'traffic jam' treats multiple diseases in mice (2026, November 19) retrieved 19 November 2026 from https://medicalxpress.com/news/2026-11-cellular-traffic-multiple-diseases-mice.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com